MIRA Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
MIRA Pharmaceuticals has a total shareholder equity of $2.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $3.0M and $796.6K respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.82m |
| Equity | US$2.22m |
| Total liabilities | US$796.61k |
| Total assets | US$3.02m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: K6S's short term assets ($2.9M) exceed its short term liabilities ($796.6K).
Long Term Liabilities: K6S has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: K6S is debt free.
Reducing Debt: K6S had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: K6S has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: K6S is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.